<DOC>
	<DOCNO>NCT02435914</DOCNO>
	<brief_summary>This study evaluate safety , efficacy , tolerability , systemic pharmacokinetics 3 different dos topical ophthalmic AGN-223575 suspension compare AGN-223575 vehicle patient dry eye disease .</brief_summary>
	<brief_title>Safety , Efficacy , Tolerability Pharmacokinetics AGN-223575 Ophthalmic Suspension Patients With Dry Eye Disease</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Signs symptom dry eye disease Has use RESTASIS and/or artificial tear eye twice day least 60 day . History glaucoma , ocular hypertension Diagnosis ocular infection Use contact lenses past 14 day expect use study Use topical ophthalmic medication past 30 day Use corticosteroid past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>